tiprankstipranks
Trending News
More News >

Genedrive’s CYP2C19 ID Kit Gains CE-Certification, Enhancing Market Reach

Story Highlights
  • Genedrive plc’s CYP2C19 ID Kit receives CE-certification under European regulations.
  • The certification enhances Genedrive’s market positioning and offers significant healthcare benefits.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Genedrive’s CYP2C19 ID Kit Gains CE-Certification, Enhancing Market Reach

Confident Investing Starts Here:

Genedrive ( (GB:GDR) ) has issued an announcement.

Genedrive plc announced the CE-certification of its Genedrive® CYP2C19 ID Kit under the European In Vitro Diagnostic Regulation, enabling its market presence in Europe and facilitating registrations in non-European countries. The kit is designed to rapidly identify patients unlikely to respond to the antiplatelet drug Clopidogrel, crucial in emergency healthcare settings. This certification is expected to enhance Genedrive’s market positioning, with potential to prevent recurrent stroke admissions and offer significant financial and productivity benefits to healthcare systems, particularly in the UK NHS.

Spark’s Take on GB:GDR Stock

According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.

Genedrive’s overall score reflects strong revenue growth and a healthy balance sheet, offset by ongoing profitability challenges and negative cash flows. Technical indicators suggest bearish momentum, while positive corporate events, including new funding and strategic partnerships, offer a potential upside.

To see Spark’s full report on GB:GDR stock, click here.

More about Genedrive

Genedrive plc is a UK-based pharmacogenetic testing company that specializes in developing and commercializing rapid, low-cost, and versatile point-of-care testing platforms. These platforms are designed to diagnose genetic variants, aiding clinicians in making informed decisions about medication choices and dosages, particularly in emergency healthcare settings. The company is at the forefront of point-of-care pharmacogenetic testing and has launched two flagship products: the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both recommended by the National Institute for Health and Care Excellence (NICE) for use in the UK NHS.

Average Trading Volume: 5,157,683

Technical Sentiment Signal: Strong Sell

Current Market Cap: £8.37M

For a thorough assessment of GDR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App